Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
RCRocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc. (RCKT)

NASDAQ Global Market · Currency in USD
$2.29 ▼ -0.02 (-0.87%)
At close: Oct 23, 4:00 PM ET. Market closed.
$2.28 ▼ -0.01 (-0.44%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$2.31
Open
$2.27
Day's Range
$2.17 – $2.29
52 Week Range
$2.17 – $5.45
Volume
1,601,101
Avg. Volume
2,054,436
Market Cap
$251.38M
Beta (5Y Monthly)
0.50
PE Ratio (TTM)
--
EPS (TTM)
-$0.15
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$5.32

Profile: Rocket Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
202
CEO
Gaurav D. Shah

Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs. It is currently progressing three ex vivo lentiviral vector therapies aimed at specific genetic conditions: Fanconi anemia, characterized by a bone marrow defect that hinders blood cell production; leukocyte adhesion deficiency-I, an inherited disorder resulting in a compromised immune system; and pyruvate kinase deficiency, a rare autosomal recessive red blood cell ailment leading to chronic non-spherocytic hemolytic anemia.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.39 · Revenue est. $200.00K
DateEst.Actual
Aug 10, 2026$0.86$1.08Beat
May 7, 2026-$0.41-$0.42Miss
Feb 26, 2026-$0.42-$0.38Beat
Nov 6, 2025-$0.48-$0.45Beat
Aug 7, 2025-$0.57-$0.59Miss
May 8, 2025-$0.59-$0.56Beat

Analyst view

Consensus price target
$5.32 ▲ +132.3%
Range $2.95 – $9.00
Rating: Buy
Buy 74% · Hold 21% · Sell 5%

Get free alerts on RCKT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.